The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Workforce
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / New Study Reveals Limitations in ANA Test Kits for Lupus

New Study Reveals Limitations in ANA Test Kits for Lupus

September 20, 2018 • By Kimberly Retzlaff

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Jarun Ontakrai / shutterstock.com

Jarun Ontakrai / shutterstock.com

The variability in serological testing for antinuclear antibodies (ANA) is under investigation after unexpected findings were reported from clinical trials of new agents to treat systemic lupus erythematosus (SLE).

You Might Also Like
  • Study Finds ANA-Negative Classification Errors Among Newly Diagnosed Lupus Patients
  • Some Lupus Tests Yield False Results
  • The Biomarkers of Lupus Disease Study
Explore This Issue
September 2018
Also By This Author
  • Methotrexate May Mitigate Inflammatory Bone Disease Note Experts at the ACR/ARHP Winter Rheumatology Symposium

In “Assay Variation in the Detection of Antinuclear Antibodies in the Sera of Patients with Established SLE,” David S. Pisetsky, MD, PhD, and his colleagues demonstrate variability in assays for identifying ANAs in patients with established SLE. First published online on March 27, 2018, in Annals of the Rheumatic Diseases, this study provides evidence that the performance characteristics of test kits can lead to assay variability.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The tests investigated included three immunofluorescence assays (IFA), an enzyme-linked immunosorbent assay (ELISA), and a bead-based multiplex assay. Study results may prompt some clinicians to consider how they interpret results of ANA assays and to adjust their testing protocols for patients with lupus.

The Research Rationale

“We had a very specific motivation for doing this study,” says lead author Dr. Pisetsky, professor of medicine and immunology at Duke University in Durham, N.C. “ANA testing has been around for a long time. The IFA for ANA determination has been identified as the so-called gold standard. But the reason to look in detail at the results from different ANA kits was the experience in clinical trials.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

One study in particular, a phase 2 trial of belimumab, failed to demonstrate statistically significant therapeutic effects of the drug in patients with established SLE. The unexpected results led the investigators to examine whether any subpopulations showed responses. The laboratory results they looked at included ANA determinations. Although ANA assays are believed to be positive in 95–99% of patients with lupus, surprisingly, they found 30% of the patients were serologically negative.

“The company went back, reanalyzed the data and saw efficacy in the people who were ANA positive,” Dr. Pisetsky explains. “In addition to ANA, anti-dsDNA [anti-double-stranded DNA] results were tested. When the company went forward in the phase 3 trial, it was for those patients who were ANA or anti-dsDNA positive. Other companies have followed this approach, and it’s not uncommon that they experience the same problem [with patients who have SLE demonstrating negative ANA results],” he says.

Because of the developments from the belimumab study and other clinical trials, “serological testing is being used as a companion diagnostic or theranostic biomarker although existing tests have not been validated for this purpose,” Dr. Pisetsky and colleagues wrote in their study. This nature of the enrollment criteria for clinical trials led them to investigate the variability of ANA test kits in patients with established SLE.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: ANA test, antinuclear antibody test, assayIssue: September 2018

You Might Also Like:
  • Study Finds ANA-Negative Classification Errors Among Newly Diagnosed Lupus Patients
  • Some Lupus Tests Yield False Results
  • The Biomarkers of Lupus Disease Study
  • Study Reveals Role of IL-17–Secreting CD4+ T Cells in Lupus

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.